Batch J, Ma A, Bird D, Noble R, Charles B, Ravenscroft P, Cameron D
Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, Australia.
Eur J Clin Pharmacol. 1990;38(5):465-7. doi: 10.1007/BF02336685.
The effect of altering the timing of gliclazide administration in relation to a meal was studied in ten type 2 (non-insulin dependent) chronically treated diabetics. Gliclazide was given 30 min before, at the start of and 30 min after breakfast or omitted altogether. Plasma gliclazide was present at greater than 2 mg/l throughout the study periods. Administration at 30 min after the meal significantly delayed the time to peak for plasma gliclazide. No significant difference was noted in plasma glucose, insulin or c-peptide patterns with any protocol. It is concluded that, in clinical practice, with chronically treated diabetics the timing of gliclazide ingestion in relation to meals is not critical.
在10名接受长期治疗的2型(非胰岛素依赖型)糖尿病患者中,研究了与进餐时间相关的格列齐特给药时间改变的影响。格列齐特在早餐前30分钟、早餐开始时、早餐后30分钟给药或完全省略给药。在整个研究期间,血浆格列齐特浓度均高于2mg/l。餐后30分钟给药显著延迟了血浆格列齐特达到峰值的时间。采用任何方案时,血浆葡萄糖、胰岛素或C肽模式均未观察到显著差异。结论是,在临床实践中,对于长期治疗的糖尿病患者,格列齐特与进餐相关的摄入时间并不关键。